Overpressured layer chromatography was combined with the highly sensitive and rapid digital autoradiography (DAR) and mass spectrometry to separate, detect, and identify H-3- and C-14-labeled deramciclane metabolites ...
详细信息
Overpressured layer chromatography was combined with the highly sensitive and rapid digital autoradiography (DAR) and mass spectrometry to separate, detect, and identify H-3- and C-14-labeled deramciclane metabolites in different biological matrixes. Several minor and major metabolites were separated from plasma and urine samples. The radioactive metabolites localized by DAR were scraped from the thin-layer chromatographic plate and transferred to a mass spectrometer for structure identification. Several metabolites were isolated and characterized, including hydroxy-N-desmethyl deramciclane, which is described in detail. The combination of techniques is efficient and has good sensitivity: about 2 mu g metabolite from a biological matrix was isolated and identified this way.
&NA;Zatosetron (LY 277359, LY 19167) is a serotonin 5-HT3receptor antagonist undergoing phase III clinical trials with Eli Lilly in the US for treatment of chronic anxiety. Phase II trials in Japan have been disco...
详细信息
&NA;Zatosetron (LY 277359, LY 19167) is a serotonin 5-HT3receptor antagonist undergoing phase III clinical trials with Eli Lilly in the US for treatment of chronic anxiety. Phase II trials in Japan have been discontinued. Zatosetron has also shown promise as an antiemetic agent and is undergoing phase II trials in the US for this indication. AUS phase II clinical trial of zatosetron failed to demonstrate significant improvement in patients with migraine when the drug was administered as a single IV infusion.
&NA;Zatosetron (LY 277359, LY 19167) is a serotonin 5-HT3 receptor antagonist undergoing phase III clinical trials with Eli Lilly in theUS for treatment of chronic anxiety. Phase II trials in Japan have been disco...
详细信息
&NA;Zatosetron (LY 277359, LY 19167) is a serotonin 5-HT3 receptor antagonist undergoing phase III clinical trials with Eli Lilly in theUS for treatment of chronic anxiety. Phase II trials in Japan have been discontinued. Zatosetron has also shown promise as an antiemetic agent and is undergoing phase II trials in the US for this indication. AUS phase II clinical trial of zatosetron failed to demonstrate significant improvement in patients with migraine when the drug was administered as a single IV infusion.
&NA;Lerisetron (F 0930RS, F 0930) is a serotonin 5-HT3receptor antagonist with potential as an antiemetic agent. Lerisetron is currently undergoing phase II trials with FAES in Spain. With the exception of Spain a...
详细信息
&NA;Lerisetron (F 0930RS, F 0930) is a serotonin 5-HT3receptor antagonist with potential as an antiemetic agent. Lerisetron is currently undergoing phase II trials with FAES in Spain. With the exception of Spain and Portugal, lerisetron is available for licensing worldwide.
暂无评论